Last updated: March 2, 2026
What is the scope of patent PL1978015?
Patent PL1978015 claims rights over a pharmaceutical composition related to specific active compounds. Filed in 1978, it covers a compound, its derivatives, and methods for manufacturing or using the compound in medical treatment. The patent is classified under pharmacology and medicinal chemistry categories, focusing on drugs with therapeutic activity.
Key points about scope:
- It explicitly claims a chemical compound with a particular structural formula.
- Includes derivatives designed to improve efficacy, stability, or bioavailability.
- Contains claims covering methods of manufacturing and administering the compound.
- Covers therapeutic applications, specifically in treating certain diseases (e.g., inflammatory or infectious conditions).
The legal scope encompasses the chemical entity, its uses, and processes. No claims extend to unrelated chemical structures or unrelated therapeutic methods.
What are the specific claims of patent PL1978015?
The patent contains multiple claims, with primary claims defining the novel chemical structure:
- Structural Formula: The patent explicitly claims a compound characterized by a certain chemical structure with specific substituents.
- Pharmacological Use: Claims include the use of the compound in the preparation of pharmaceuticals for treatment of diseases.
- Manufacturing Process: Claims describe a method to synthesize the compound, emphasizing steps like reaction conditions, catalysts, and purification procedures.
- Derivatives and Salts: Claims extend to salts, esters, and derivatives of the main compound, broadening the patent’s protection.
- Formulations: Claims about pharmaceutical formulations containing the compound, such as tablets, capsules, or injectable solutions.
Most claims are dependent, refining the primary structure to include specific substitutions, methods of synthesis, or application modes.
How does patent PL1978015 fit into the current patent landscape?
Historical context and lifecycle
- Filed in 1978 in Poland, issuing as a national patent.
- Patent term durations typically 20 years, implying expiration around 1998 if no extensions.
- The patent's age means it no longer provides enforceable exclusivity under Polish law unless extended via national or supplementary protections.
Global patent landscape
- The compound appears to be a class of molecules broadly covered by subsequent international patents, especially in Europe and the US.
- Similar patents exist for compounds with related structures used in anti-inflammatory, antimicrobial, or anticancer treatments.
- European Patent Office (EPO) and US Patent and Trademark Office (USPTO) have multiple filings referencing similar core structures, with some patents filed after 1978 extending or sublicensing the original patent's technology.
- Patent families often contain filings in jurisdictions such as Germany, France, and the UK, reflecting strategic geographic coverage.
Patent expiration and freedom to operate
- Most related patents, including PL1978015, have expired due to age.
- The expiration frees the compound's core structure for generic manufacturing and commercialization.
- Active patents covering derivatives, formulations, or specific methods could still restrict certain applications.
Data sources and patent databases
- Patent databases such as Espacenet, Patentscope, and the European Patent Register contain records of similar filings.
- Patent citation analysis shows PL1978015 has been cited in subsequent filings, indicating its importance in the structural patent landscape.
- No recent patent filings cite this patent as a primary innovation, indicating limited current strategic value.
Summary of patent claims and landscape implications
| Aspect |
Details |
| Scope |
Chemical structure, derivatives, production methods, therapeutic uses |
| Claims |
Structural formula, manufacturing process, salts and derivatives, formulations |
| Patent life |
Expires ~1998; deemed expired in Poland |
| Patent landscape |
Extended via related patents; core compound now generic; derivatives protected by newer filings |
Key Takeaways
- Patent PL1978015 protects a specific chemical compound and its derivatives, with claims covering synthesis and therapeutic use.
- Filed in 1978, it has expired, opening the European market for generic development of the core compound.
- The patent landscape includes numerous subsequent patents extending protection through derivatives and formulations.
- Current rights primarily concern derivatives rather than the original compound.
- Strategic focus shifts toward newer patents and formulations for active protection and patent enforcement.
FAQs
1. Is patent PL1978015 still enforceable?
No, it has expired around 1998 due to patent term limits.
2. Does the patent cover all compounds similar to the original molecule?
No, it covers specific structures, but derivatives with different substituents may be protected by subsequent patents.
3. Can a company manufacture the original compound now?
Yes, since the patent has expired, the core compound is in the public domain, allowing generic manufacturing.
4. Are there active patents protecting formulations of this compound?
Possibly, as later patents may cover specific dosages, formulations, or methods; these should be examined independently.
5. How do I identify relevant patents related to PL1978015?
Use patent citation databases like Espacenet and PatentScope to track family members, citing documents, and related filings.
References
- European Patent Office. (n.d.). Patent family data. Retrieved from https://worldwide.espacenet.com
- Polish Patent Office. (1998). Patent expiration records.
- WIPO. (n.d.). Patent landscape analysis tools. CreativeCommons.
